Are there any drug interactions between subcutaneous retatrutide (0.1 ml of a 12 mg powder reconstituted in 2.5 ml) and hormone replacement therapy with 0.5 mg estradiol and 100 mg progesterone in a postmenopausal woman?

No Clinically Significant Drug Interactions Between Retatrutide and HRT

There are no known or documented drug interactions between subcutaneous retatrutide and hormone replacement therapy consisting of estradiol and progesterone. Retatrutide is a triple hormone receptor agonist (GIP/GLP-1/glucagon) used for obesity management, and its mechanism of action does not interfere with sex hormone pathways or metabolism 1, 2.

Retatrutide Mechanism and Safety Profile

• Retatrutide acts on glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors to promote weight loss through appetite suppression and metabolic effects 1.
• The most common adverse events are gastrointestinal (nausea, diarrhea, vomiting), which are dose-related and mostly mild to moderate in severity 1, 2.
• Dose-dependent increases in heart rate peak at 24 weeks and decline thereafter, but this is unrelated to estrogen or progesterone therapy 1.

HRT Components and Metabolism

• Your HRT regimen of 0.5 mg estradiol and 100 mg progesterone is metabolized primarily through hepatic pathways involving cytochrome P450 enzymes 3, 4.
• Retatrutide does not undergo significant hepatic metabolism and is not a substrate, inducer, or inhibitor of cytochrome P450 enzymes 1.
• Transdermal estradiol bypasses hepatic first-pass metabolism entirely, further eliminating any theoretical interaction risk 5, 4, 6.

Cardiovascular Considerations

• The cardiovascular safety profile of your HRT regimen is most favorable when using transdermal estradiol rather than oral formulations, as transdermal delivery does not increase venous thromboembolism risk (OR 0.9 vs. OR 4.2 for oral) 5, 6.
• Retatrutide causes a transient increase in heart rate that peaks at 24 weeks, but this effect is independent of HRT and does not amplify cardiovascular risks associated with estrogen therapy 1.
• If you are under 60 years old or within 10 years of menopause, the risk-benefit profile of combined transdermal estradiol-progesterone therapy remains highly favorable 3, 4.

Practical Management Recommendations

• Continue both medications without dose adjustment, as no pharmacokinetic or pharmacodynamic interactions exist 1, 2.
• Monitor for gastrointestinal side effects from retatrutide (nausea, diarrhea), which are unrelated to HRT and typically improve over 4-8 weeks 1, 2.
• Ensure you are taking adequate progestogen protection (at least 100-200 mg micronized progesterone for 12-14 days per month if using sequential regimen, or daily if using continuous regimen) to prevent endometrial hyperplasia from the estradiol component 3, 4.
• Track your heart rate during the first 24 weeks of retatrutide therapy, as dose-dependent increases are expected but unrelated to HRT 1.

Critical Pitfalls to Avoid

• Do not discontinue HRT due to concerns about retatrutide interactions—there is no evidence of any interaction, and stopping HRT abruptly can cause severe vasomotor symptom rebound 3, 4.
• Do not switch from transdermal to oral estrogen while on retatrutide, as oral estrogen carries significantly higher cardiovascular and thrombotic risks (4-fold increase in VTE risk) that are independent of retatrutide 5, 6.
• Verify that your progesterone dose and duration are adequate for endometrial protection (minimum 12 days per month for sequential regimens), as this is unrelated to retatrutide but critical for HRT safety 3, 4.